AKT1 and prostate cancer: Own previous work revealed that cells with overexpression of the clinically relevant PH-domain mutant AKT1-E17K with aberrant activation of AKT accelerated DSB repair and improved the survival of TRAMPC1 prostate cancer cells (TrC1) upon IR (33).